Pharmaceuticals

Global Hormone Therapy Market Overview 2024: Size, Drivers, And Trends

February 8, 2024 by The Business Research Company

The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

The hormone therapy market is witnessing significant growth driven by the surge in hormone imbalance disorders.

Hormone imbalance disorders lead to excessive or insufficient hormone production, including conditions like hypothyroidism, hypogonadism, and growth hormone deficiency.
Treatments such as estrogen replacement, testosterone replacement, and insulin therapy are pivotal in managing hormone imbalance disorders.
Incidences of hormone imbalances have risen notably, with reports indicating a 19% increase in hormone imbalances compared to two years ago.

Key Players in the Hormone Therapy Market

Major companies are contributing to the expansion of the hormone therapy market, including:

Abbott Laboratories
Bayer AG
Eli Lilly and Company
F. Hoffmann-La Roche
Merck KGaA
Novartis AG
Pfizer Inc.
Abbvie Inc.
Teva Pharmaceutical Industries Ltd.
Others: Perrigo Company Plc., Cipla Inc., Sun Pharmaceuticals Industries Ltd., and more.

Innovative Treatments Drive Evolution In Hormone Therapy Market

Product innovation is shaping the hormone therapy landscape, with companies focusing on novel treatments.

Key players are launching innovative therapies to address hormone imbalance disorders and alleviate symptoms while reducing side effects.
Example: Myovant Sciences and Pfizer received FDA approval for MYFEMBREE, a medication managing excessive monthly bleeding in premenopausal women caused by uterine fibroids.
MYFEMBREE offers significant symptom relief with once-daily administration and supportive patient assistance programs.

Grünenthal Enhances Hormone Therapy Portfolio With Nebido Acquisition

Grünenthal Group’s acquisition of Nebido from Bayer AG strengthens its hormone therapy offerings.

The acquisition, valued at approximately $547.4 million, bolsters Grünenthal’s EBITDA by an estimated $107.2 million.
Nebido’s addition aligns with Grünenthal’s strategic expansion initiatives, complementing its existing portfolio.
Grünenthal’s recent acquisitions also include global rights to Qutenza, Zomig, Vimovo, Crestor, and Nexium, reflecting its commitment to growth.

Market Segmentation and Geographic Trends

The hormone therapy market is segmented based on therapy, route of administration, indication, and distribution channel.

By Therapy: Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement.
By Route of Administration: Oral, Parenteral, Other Routes of Administration.
By Indication: Menopause, Hypothyroidism, Growth Hormone Deficiency, Other Indications.
By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies And Stores, Online Pharmacies.

Regional Insights: North America Dominates

North America emerged as the largest region in the hormone therapy market in 2023.

The region’s dominance is attributed to advanced healthcare infrastructure, increasing prevalence of hormone-related disorders, and high awareness levels.
North America’s robust market position underscores the region’s significant contribution to the global hormone therapy landscape.

Future Outlook and Conclusion

The hormone therapy market is poised for substantial growth driven by evolving treatment approaches and rising demand.

Continued research and development, regulatory adaptations, and consumer education are anticipated to shape market dynamics.
The market’s expansion reflects the growing emphasis on personalized medicine, wellness, and longevity.
As innovative therapies continue to emerge and market players expand their portfolios, the hormone therapy market is positioned for sustained growth in the coming years.

You may also like